Seer, Inc. Projects 2026 Revenue Between $13.5M and $14.5M Amid Commercial Restructuring
Seer, Inc. (SEER) has provided a revenue outlook for 2026, forecasting between $13.5 million and $14.5 million. This guidance follows a strategic refocusing of the company's commercial efforts initiated after a review by a special committee. Despite the restructuring, CEO Omid Farokhzad reported steady demand from established customers for consumables. Additionally, the company noted successful adoption of its Proteograph Product Suite by new large biopharma clients for use in internal laboratory settings.
Topics: biopharma customers earnings call product adoption revenue drivers
Read the full article at Seeking Alpha
Part of the story Seer outlines $13.5M-$14.5M 2026 revenue outlook while refocusing commercial efforts after special committee review (2 articles)